Background Early pregnancy loss is a common event in the first trimester, occurring in 15%–
20% of confirmed pregnancies. A common evidence-based medical regimen for early
pregnancy loss uses misoprostol, a prostaglandin E1 analog, with a dosage of 800 μg, self-
administered vaginally. The clinical utility of this regimen is limited by suboptimal
effectiveness in patients with a closed cervical os, with 29% of patients experiencing early
pregnancy loss requiring a second dose after 3 days and 16% of patients eventually …

Objective To evaluate characteristics associated with treatment success in women receiving
medical management for early pregnancy loss (EPL). Design We performed a secondary
analysis of a randomized trial of 300 participants 1 comparing mifepristone-misoprostol to
misoprostol alone for EPL treatment. Materials and Methods We tested the ability of
characteristics associated with misoprostol success in a previous study 2, vaginal bleeding
and parity of 0 or 1, to discriminate successful from failed treatment in each arm of our study …